BR112012013371A2 - peptídeo mybl2 e vacinas contendo os mesmos. - Google Patents

peptídeo mybl2 e vacinas contendo os mesmos.

Info

Publication number
BR112012013371A2
BR112012013371A2 BR112012013371A BR112012013371A BR112012013371A2 BR 112012013371 A2 BR112012013371 A2 BR 112012013371A2 BR 112012013371 A BR112012013371 A BR 112012013371A BR 112012013371 A BR112012013371 A BR 112012013371A BR 112012013371 A2 BR112012013371 A2 BR 112012013371A2
Authority
BR
Brazil
Prior art keywords
peptides
prevention
mybl2
present
cytotoxic
Prior art date
Application number
BR112012013371A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ohsawa
Sachiko Yoshimura
Takuya Tsunoda
Tomohisa Watanabe
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112012013371A2 publication Critical patent/BR112012013371A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112012013371A 2009-12-04 2010-12-02 peptídeo mybl2 e vacinas contendo os mesmos. BR112012013371A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26687109P 2009-12-04 2009-12-04
PCT/JP2010/007028 WO2011067933A1 (en) 2009-12-04 2010-12-02 Mybl2 peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
BR112012013371A2 true BR112012013371A2 (pt) 2016-12-13

Family

ID=44114795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013371A BR112012013371A2 (pt) 2009-12-04 2010-12-02 peptídeo mybl2 e vacinas contendo os mesmos.

Country Status (14)

Country Link
US (1) US20120328638A1 (enExample)
EP (1) EP2507257A4 (enExample)
JP (1) JP2013512659A (enExample)
KR (1) KR20120114284A (enExample)
CN (1) CN102753567A (enExample)
AU (1) AU2010327891A1 (enExample)
BR (1) BR112012013371A2 (enExample)
CA (1) CA2782484A1 (enExample)
IL (1) IL219927A0 (enExample)
MX (1) MX2012006376A (enExample)
RU (1) RU2012127762A (enExample)
SG (1) SG181108A1 (enExample)
TW (1) TW201200525A (enExample)
WO (1) WO2011067933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623657B (zh) * 2018-05-11 2021-02-12 苏州大学 多肽、重组dna分子、重组载体、外泌体及其应用
WO2024209270A2 (en) * 2023-04-07 2024-10-10 Infinitopes Limited Methods and compositions for cancer treatment using recombinant polypeptides
CN119859688A (zh) * 2025-01-20 2025-04-22 杭州树源生命科学有限公司 环状RNA Hsa_circ_0006332在食管鳞状细胞癌诊断和治疗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN100352842C (zh) * 2002-10-31 2007-12-05 詹森药业有限公司 对促肾上腺皮质激素释放激素刺激的应答而表达增加的基因
US7847060B2 (en) * 2005-02-25 2010-12-07 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
SG181108A1 (en) 2012-07-30
EP2507257A1 (en) 2012-10-10
US20120328638A1 (en) 2012-12-27
MX2012006376A (es) 2012-07-10
AU2010327891A1 (en) 2012-06-21
EP2507257A4 (en) 2013-04-03
TW201200525A (en) 2012-01-01
RU2012127762A (ru) 2014-01-10
CN102753567A (zh) 2012-10-24
CA2782484A1 (en) 2011-06-09
KR20120114284A (ko) 2012-10-16
JP2013512659A (ja) 2013-04-18
WO2011067933A1 (en) 2011-06-09
IL219927A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
IN2014DN09963A (enExample)
NZ708990A (en) Method for activating helper t cell
BR112015021828A2 (pt) Peptídeos de kntc2 e vacinas que contêm os mesmos
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
BR112015004349A2 (pt) peptídeos de ube2t e vacinas contendo os mesmos
BR112012013371A2 (pt) peptídeo mybl2 e vacinas contendo os mesmos.
PH12014500720A1 (en) Topk peptides and vaccines including the same
JP2013523084A5 (enExample)
JP2015529219A5 (enExample)
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
MX2011012013A (es) Peptidos ttk y vacunas que incluyen los mismos.
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
JP2014506114A5 (enExample)
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
BR112013005448A2 (pt) peptídeos de ttll4 e vacinas contendo os mesmos.
BR112012024997A2 (pt) peptídeos ect2 e vacinas incluindo os mesmos
MX2011010191A (es) Peptidos c6orf167 y vacunas que continen los mismos.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
JP2013521761A5 (enExample)
BR112013009526A2 (pt) peptídeos de wdhd1 e vacinas incluindo os mesmos
BR112015012234A2 (pt) Peptídios sema5b e vacinas contendo os mesmos
MX2012011666A (es) Peptidos cluap1 y vacunas que incluyen los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]